Concepedia
Author
Yousra Kherabi
Also Known As
Kherabi Yousra, Y. Kherabi, Yousra KHERABI, Yousra Kherabi
63
Publications
2.7K
Citations
14
H-Index
24
Concepts
All Affiliations
1
3
1.2K
2
18
21
4
5
×
All Concepts
7
1.3K
Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19
Eve Garrigues, Paul Janvier, Yousra Kherabi, +14
Journal of Infection
Quality Of LifeLong CovidHealth-related QualityCovid-19 PandemicOutcomes Research +4
2020
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern
Thibault Fiolet, Yousra Kherabi, Conor MacDonald, +2
Mrna VaccinesImmunologyCovid-19 VaccinesCovid-19 EpidemiologyBroad-spectrum Vaccines +14
2021
Machine learning to predict antimicrobial resistance: future applications in clinical practice?
Yousra Kherabi, Michaël Thy, Donia Bouzid, +3
Infectious Diseases Now
2024
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe
Gunar Günther, Lorenzo Guglielmetti, Yousra Kherabi, +2
Clinical Microbiology and Infection
Pulmonary TuberculosisDrug Resistance AnalysisRifampicin-resistant TuberculosisHealth SciencesPharmacology +10
Streptococcal and Staphylococcus aureus prosthetic joint infections: are they really different?
Yousra Kherabi, Valérie Zeller, Younes Kerroumi, +4
BMC Infectious Diseases
2022
17
The ADAMTS13 <sup>1239–1253</sup> peptide is a dominant HLA-DR1-restricted CD4 <sup>+</sup> T-cell epitope
Laurent Gilardin, Sandrine Delignat, Ivan Peyron, +17
Haematologica
2017
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
Yousra Kherabi, Mathilde Fréchet-Jachym, Christophe Rioux, +5
Emerging infectious diseases
13
Page 1